Cargando…
LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma
BRAF inhibitors (iBRAF) are a therapeutical option for pediatric Low-Grade-Gliomas (pLGG), but their chronic use may be needed to prevent tumor regrowth. Growth hormone (GH) replacement in children with GH deficiency (GHD) and on oncological treatment is under debate. We report on our experience of...
Autores principales: | Verrico, Antonio, Crocco, Marco, Casalini, Emilio, Ramaglia, Antonia, Rossi, Andrea, Iurilli, Valentina, Piccolo, Gianluca, Milanaccio, Claudia, Garrè, Maria Luisa, Iorgi, Natascia Di |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164719/ http://dx.doi.org/10.1093/neuonc/noac079.352 |
Ejemplares similares
-
LGG-35. Dyslipidemia in children treated with BRAF inhibitors for brain tumor, a new side effect? A single center retrospective study
por: Crocco, Marco, et al.
Publicado: (2022) -
LGG-34. Nephrological impact of BRAF inhibitors in a pediatric population of central nervous system tumors: a single institution experience
por: Verrico, Antonio, et al.
Publicado: (2022) -
LGG-40. NATURAL COURSE AND MANAGEMENT OF SMALL ASYMPTOMATIC LESION SUSPECTED OF LOW-GRADE GLIOMA IN CHILDREN
por: Muroi, Ai, et al.
Publicado: (2020) -
LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020) -
LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION
por: Uchida, Hiroyuki, et al.
Publicado: (2020)